Outcomes of antiretrovirals used as the third drug in subgroups of treatment
naive individuals living with HIV

Background

Although outcomes of ART have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real-world settings are limited.

RESPOND aimed to compare shorter term (12 months) virologic and immunologic outcomes and longer-term clinical events of AIDS/death in ART-naïve persons starting ART in RESPOND with either an INSTI, PI/b or NNRTI regimen in a priori defined relevant subgroups defined by age, CD4 count, severe immunosuppression (AIDS or CD4<200/mm³) and VL.

Methods

• Logistic regression compared virologic and immunologic outcomes at 12±3 months after starting ART with an INSTI, contemporary NNRTI or PI/b treatments with 2 nucleos(t)ides after 1/1/2012

• Composite treatment outcome [cTO] defined success as VL<200 copies/mL with no regimen change, AIDS or death. Immunologic success was defined as CD4 >750 cells/mm³ or 33% increase where baseline CD4 >500 cells/mm³

• Poisson regression compared AIDS/death >14 days after starting ART

• Interactions between ART class and age, CD4 count, VL were determined for each endpoint.

Results

Of 5102 ART-naïve persons in RESPOND, 45.3% started INSTIs, 26.2% PI/b and 28.6% NNRTIs (Table). The most commonly used nucleoside backbone was TDF/FTC (n=3655; 71.7%) and ABC/3TC (n=905; 17.7%). Those starting PI/b regimens were more likely to be female, have a higher VL and lower CD4 count nadir. Those starting INSTIs had ART start more recently.

Results ctd

Outcomes are summarized in the Figure

• 2667 (57.9%; 95% CI 56.0–59.8%) achieved cTO success; 1715 on INSTIs (61.4%; 95% CI 58.6–64.1%), 634 (48.3%; 95% CI 44.5–52.4%) on PI/b and 858 on NNRTIs (62.3%; 95% CI 59.0–65.5%).

• 879 (22.6%; 95% CI 21.3–24.0%) achieved immunologic success; 441 on INSTIs (27.1%; 95% CI 25.0–29.3%), 199 (18.1%; 95% CI 15.8–20.4%) on PI/b and 239 on NNRTIs (20.6%; 95% CI 18.3–22.9%).

• 256 persons had a new AIDS diagnosis or died >14 days after initiation of ART during 15082 PYFU; incidence rate 17.0/1000 PYFU (95% CI 14.9–19.1). The incidence was highest for INSTIs (21.2; 95% CI 17.2–25.3), followed by PI/b (18.1; 95% CI 14.4–21.8) and lowest in NNRTI (11.7; 95% CI 8.7–14.7).

• cTO, immunologic success and clinical failure were completely consistent across age groups (<40, 40-50 and >50 years), CD4 count at starting ART (<350 versus >350 cells/mm³), VL at starting ART (<100,000 versus >100,000 copies/mL) or in those with/without severe immunosuppression - all interactions were non-significant (p>0.05).

Limitations and Strengths

• The main limitations are confounding by indication and not being adequately powered to look at the impact of individual ARVs

• The major strengths were the heterogeneity, the inclusion of routine clinic populations, and inclusion of clinical events as an endpoint

Conclusions

Virologic, immunologic and clinical outcomes in ART-naïve participants were similar for different ART classes irrespective of age, immunosuppression or VL at ART initiation. While confounding by indication cannot be excluded, this provides reassuring evidence that such subpopulations will equally benefit from ART, regardless of ART class.